Daiichi Sankyo : REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer(193.7KB -April 03, 2024 at 08:18 am EDT : vimarsana.com

Daiichi Sankyo and Merck & Co., Inc, Rahway, NJ, USA announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the efficacy and safety of...

Related Keywords

United States , Tokyo , Japan , Daiichi Sankyo , Merck Co Inc , Press Release , Raludotatug Deruxtecan Initiated , Platinum Resistant Ovarian Cancer Tokyo , Basking Ridge ,